



UNITED STATES PATENT AND TRADEMARK OFFICE

CC

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/698,402	11/03/2003	Jean-Louis Escary	60711.000025	2689
21967	7590	06/21/2005	EXAMINER	
			GALVEZ, JAMES JASON	
		ART UNIT		PAPER NUMBER
		1647		
DATE MAILED: 06/21/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/698,402	ESCARY, JEAN-LOUIS
	<b>Examiner</b>	<b>Art Unit</b>
	J. Jason Galvez	1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 3/19/2004.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-56 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) \_\_\_\_\_ is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) 1-56 are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: \_\_\_\_\_

**DETAILED ACTION**

***Election/Restrictions***

Restriction to one of the following inventions is required under 35 U.S.C. 121:

1. Claims 1-35 and 53, drawn to single nucleotide polymorphisms (SNPs),  
vectors, host cell and therapeutic agents comprising SNPs, vectors or  
host cells, classified in class 435, subclass 69.1/320.1/325, class 536,  
subclass 23.5 and class 514, subclass 44.
2. Claims 36-38 and 54-56, drawn to methods of genotyping/diagnosing  
disease based on SNPs, classified in class 435, subclass 6.
- 10 3. Claims 39-47 and 53, drawn to polypeptides encoded by SNPs and  
therapeutic agents comprising polypeptides encoded by SNPs, classified  
in class 530, subclass 350.
4. Claim 48, drawn to antibodies directed to polypeptides encoded by SNPs,  
classified in class 530, subclass 387.1.
- 15 5. Claims 49-50, drawn to methods of treatment using polypeptides encoded  
by SNPs, classified in class 514, subclass 2.
6. Claims 51-52, drawn to methods of identifying compounds similar to  
polypeptides encoded by SNPs, classified in class 514, subclass 2.

The inventions are distinct, each from the other because of the following reasons:

20 Inventions 1 and 2 are related as product and process of use. The inventions  
can be shown to be distinct if either or both of the following can be shown: (1) the  
process for using the product as claimed can be practiced with another materially

Art Unit: 1647

different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in a materially different process, such as the production of recombinant production of polypeptides.

5       In addition, the inventions 1 and 2 have a separate status in the art as shown by their different classifications. Moreover, in the instant case, the search for the claimed polynucleotide and methods of genotyping/diagnosing are not coextensive. Inventions 1 and 2 are separate and distinct by way of their different classifications and divergent subject matter. Therefore, searching inventions 1 and 2 together would impose a  
10      serious burden on the Examiner and USPTO resources.

Inventions 1 (polynucleotides) and 3 (polypeptides) are distinct from one another because polynucleotides, which are composed of purine and pyrimidine units, are structurally distinct molecules than polypeptides, which are composed of amino acids; any relationship between a polynucleotide and a polypeptide is dependent upon the  
15      information provided by the nucleic acid sequence open reading frame as it corresponds to the primary amino acid sequence of the encoded polypeptide. In addition, polypeptides can be made by another materially different process than from recombinant polynucleotide expression, such as chemical synthesis or isolation/purification from natural sources.

20       Furthermore, searching inventions 1 and 3 together would impose a serious search burden. In the instant case, the search of the polynucleotides and polypeptides are not coextensive. Inventions 1 and 3 have a separate status in the art as shown by

Art Unit: 1647

their different classifications. In cases such as this one where descriptive sequence information is provided, the sequences are searched separately in appropriate databases. There is also a search burden in regards to non-patent literature. Prior to the concomitant isolation and expression of the sequence of interest there may be

- 5 journal articles devoted solely to polypeptides that would not have described the polynucleotide. Similarly, there may have been "classical" genetics papers that expressed no knowledge of a polypeptide but spoke of its corresponding gene.

Inventions 1 (polynucleotides) and 4 (antibodies) are distinct from another because polynucleotides, which are composed of purine and pyrimidine units, are 10 structurally distinct molecules than antibodies, which are composed of amino acids consisting of 2 light and 2 heavy chains containing constant and variable regions, and including framework regions which act as a scaffold for the 6 complementarity determining regions (CDRs).

Furthermore, the inventions directed to polynucleotides and antibodies have a 15 separate status in the art as shown by their different classifications. For the reasons given above, searching inventions 1 and 4 together would impose a serious search burden on the Examiner and USPTO resources since a search of the polynucleotides would not be used to determine the patentability of the antibodies, and vice-versa.

Inventions 1 and 5/6 are unrelated because the products of invention 1 are not 20 used or otherwise involved in the methods of inventions 5 or 6.

Inventions 2 and 3/4 are unrelated because the methods of invention 2 do not use or otherwise involve the products of inventions 3 or 4.

Inventions 2, 5 and 6 are each unrelated to one another. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed

- 5 as capable of use together. Inventions 2, 5 and 6 are each directed towards different methods that have different modes of operation, different functions, different starting materials, different effects, and/or different outcome measures.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and/or  
10 separate search requirement based on particular aspects of the inventions, e.g. inventions using different starting materials and inventions have different effects, it would impose a serious search burden on the Examiner and USPTO resources to search the inventions together.

Inventions 3 and 4 are distinct from one another because the polypeptides of  
15 inventions 3 and the antibodies of invention 4 are directed to distinct chemical entities. While the inventions 3 and 4 are polypeptides, in this instance the polypeptides of invention 3 are most likely a single chain molecule, whereas the polypeptides of invention 4 encompass antibodies including IgG which comprises 2 heavy and 2 light chains containing constant and variable regions, and including framework regions which  
20 act as a scaffold for the 6 complementarity determining regions (CDRs) that function to bind an epitope. Thus the polypeptides of invention 3 and the antibodies of the invention 4 are structurally distinct molecules; any relationship between a polypeptide

Art Unit: 1647

and an antibody is dependent upon the correlation between the scope of the polypeptides that the antibody binds and the scope of the antibodies that would be generated upon immunization with the polypeptide.

Furthermore, searching the inventions 3 and 4 would impose an undue search burden. The inventions have a separate status in the art as shown by their different classifications. A polypeptide and an antibody that binds to the polypeptide require different searches. An amino acid sequence search of the full-length protein is necessary for a determination of novelty and unobviousness of the protein. However, such a search is not required to identify the antibodies. In addition, the technical literature search for polypeptides and antibodies may not be coextensive, e.g. antibodies may be characterized in the technical literature prior to discovery of, or sequence of, their binding target.

Inventions 3 and 5/6 are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product of invention 3 can be used in a materially different process, such as the production of monoclonal antibodies.

In addition, the inventions 3 and 5/6 have a separate status in the art as shown by their different classifications. Moreover, in the instant case, the search for the claimed products and methods treatment or methods of screening using the claimed

Art Unit: 1647

products is not coextensive. Inventions 3 and 5/6 are separate and distinct by way of their different classifications and divergent subject matter. Therefore, searching the inventions together would impose a serious burden on the Examiner and USPTO resources.

5        Inventions 4 and 5/6 are unrelated because the products of invention 1 are not used or otherwise involved in the methods of inventions 5 or 6.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

A) c42t SNP

B) g43a SNP

10      C) c82t SNP

D) a123t SNP

E) g152c SNP

F) t174c SNP

G) g292c SNP

15      H) a516G SNP

I) c641g SNP

J) g798c SNP

K) g1009a SNP

Although there are no provisions under the section for "Relationship of

20      Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different products, restriction is deemed to be proper because these products constitute patentably distinct inventions for the following reasons. Applicant is claiming specific

Art Unit: 1647

SNPs at positions 42, 43, 82, 123, 152, 174, 292, 516, 641, 798 and 1009 of SEQ ID

NO: 1. Each of the SNPs claimed constitute a different sequence and patentably distinct inventions. Therefore, searching all of the sequences in a single patent application would provide an undue search burden on the Examiner and the USPTO's

5 resources because of the non-coextensive nature of these searches.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

M) polypeptides encoded by SNPs leading to the amino acid change Q28R

N) polypeptides encoded by SNPs leading to the amino acid change Q70E SNP

10 O) polypeptides encoded by SNPs leading to the amino acid change C112S SNP

Although there are no provisions under the section for "Relationship of

Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different

products, restriction is deemed to be proper because these products constitute

patentably distinct inventions for the following reasons. Applicant is claiming specific

15 mutated proteins at positions 28, 70 and 112 SEQ ID NO: 2. Each of the point

mutations claimed constitute a different sequence and patentably distinct inventions.

Therefore, searching all of the sequences in a single patent application would provide

an undue search burden on the Examiner and the USPTO's resources because of the

non-coextensive nature of these searches.

20 The Examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is

subsequently found allowable, withdrawn process claims that depend from or otherwise

include all limitations of the allowable product claim will be rejoined in accordance with

the provisions of MPEP § 821.04. **Process claims that depend from or otherwise**

**include all the limitations of the patentable product** will be entered as a matter of

right if the amendment is presented prior to final rejections or allowance, whichever is

5 earlier. Amendments submitted after final rejection is governed by 37 CFR 1.116;

amendments submitted after allowance is governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product

claims and the rejoined process claims will be withdrawn, and the rejoined process

claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus,

10 to be allowable, the rejoined claims must meet all criteria for patentability including the

requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is

found allowable, an otherwise proper restriction requirement between product claims

and process claims may be maintained. Withdrawn process claims that are not

commensurate in scope with an allowed product claim will not be rejoined. See

15 "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re*

*Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order

to retain the right to rejoinder in accordance with the above policy, Applicant is advised

that the process claims should be amended during prosecution either to maintain

dependency on the product claims or to otherwise include the limitations of the product

20 claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections under 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the Examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must

- 5 include an election of the invention to be examined even though the requirement may be traversed (37 CFR 1.143). Applicant is required to elect an invention from 1-6 and A-K and M-O. If Applicant wishes to elect more than one sequence, A-K and M-O, Applicant must specifically claim each sequence and provide relevant information providing support for searching the sequences together.

- 10        Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

15

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **J. Jason Galvez, Ph.D.** whose telephone number is  
20 **571-272-2935**. The examiner can normally be reached Monday through Friday 9 AM to 5 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Brenda Brumback, Ph.D.** can be reached at **571-272-0887**.

The fax phone number for the organization where this application or proceeding is assigned is **571-273-8300**. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or

5 Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at **866-217-9197** (toll-free).

10

15 JJG  
6/16/2005

*Bridget E. Bunner*  
patent examiner